Operable squamous esophageal cancer: current results from the East.

Department of Thoracic Surgery, Cancer Hospital (Institute), Beijing, People's Republic of China.
World Journal of Surgery (Impact Factor: 2.23). 01/1994; 18(3):347-54. DOI: 10.1007/BF00316813
Source: PubMed

ABSTRACT From 1958 through 1992 a total of 3603 patients underwent surgery for esophageal squamous cell carcinoma in our department. Among these patients 3099 resections were performed, for an overall resectability of 86.0%. Of the resections, 2341 (75.5%) were classified as curative and 758 (24.5%) palliative. The overall morbidity and 30-day mortality rates were 23.4% and 3.8%, respectively. For resected cases the mortality was 4.0%. The more than 5-year follow-up rate of patients with resection was 97%. The actual 5-, 10-, and 15-year survival rates were 30.4%, 23.6%, and 17.9%, respectively. Recurrence or metastasis remained the cause of death in 60.9% and 25.5% of patients who lived longer than 5 years and 15 years, respectively, after operation. The TNM staging, lymph node metastasis, extra-esophageal invasion, tumor differentiation, tumor length, and category of operation were major determinants influencing long-term prognosis. The left thoracotomy approach was used exclusively in 2613 cases (84.3% of all resected cases) in which intrathoracic resections and anastomoses were performed. The stomach was used as a substitute for the esophagus in 98.8% of the resected cases compared with 1.2% colon transplants. The former procedure was far safer than the latter. Above-average results presented in this paper support the surgical policy we have pursued thus far: to resect the primary tumor by partial or subtotal esophagectomy and to remove all lymph nodes wherever they were found in all patients with disease earlier than stage III. Early detection and early treatment no doubt are the only ways to materially improve the long-term surgical results.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Esophagectomy is the mainstay of curative treatment for localized esophageal cancer. However, what constitutes cure is not well defined. This study was undertaken to characterize actual 5-year survivors following esophagectomy and to determine prognostic factors for disease-specific survival (DSS) from 60 months. Between 1987 and 2004, 398 consecutive patients underwent esophagectomy and had potential for 5 years follow-up. Clinicopathological factors associated with DSS from 5 years onward were analyzed. Median DSS was 25 months. Neoadjuvant therapy was administered to 159 of 398 (40%). There were 114 of 398 (29%) actual 5-year survivors. On multivariate analysis, 5-year survivors were significantly more likely to have lower T classification, N classification, and R0 resections compared with patients who died less than 5 years after surgery. There were 66 of 398 patients (17%) with positive margins, and 6 of these were 5-year survivors. Of the 114 5-year survivors, 17 (15%) subsequently died of esophageal cancer. Prognostic factors for DSS after surviving 5 years were age and T classification for patients treated with neoadjuvant therapy and surgery alone, respectively. Powerful prognostic factors from time of treatment, including nodal status, were no longer prognostic factors after surviving to 5 years. No single clinicopathological variable negated survival to 5 years. Prognostication once surviving 5 years is difficult. The majority of 5-year survivors can be considered cured of esophageal cancer.
    Annals of Surgical Oncology 01/2011; 18(6):1766-74. · 4.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oesophageal replacement in patients following distal gastrectomy (DGE) remains a surgical challenge, and the standard option is the colonic or jejunal transplant. However, in some cases, it is possible (or mandatory) to utilize the remnant stomach for oesophagoplasty (EP). This method preserves some advantages of the gastric EP in comparison with the bowel EP. During recent years, several papers have been published in English regarding remnant stomach EP, and different aspects of this procedure have been discussed. However, there is still no comprehensive literature review analysing the possible EP approaches using the remnant stomach. A multilingual literature search (database and manual) to collect and classify the currently available data regarding remnant stomach EP following DGE and its subsequent analysis was carried out. There are a number of principally different methods of a remnant stomach EP: (1) mobilization of the remnant stomach with the spleen and tail of the pancreas with its transposition into the left hemithorax; (2) mobilization of the remnant stomach after splenectomy; (3) implementation of a reversed gastric tube, tailored from the major curve; (4) the use of a transplant fed from the right gastric and right gastroepiploic arteries; (5) the use of a transplant fed from the left gastric and short gastric arteries; (6) complete mobilization of the remnant stomach; (7) direct revascularization of the gastric stump conduit. The excellent plastic potential and rich vascularization of the stomach justify its use for EP, even after prior DGE. The majority of the methods of gastric stump EP are less well developed but should be investigated further.
    European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery 07/2012; · 2.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We conducted a genome-wide scan of SNPs to identify variants associated with length of survival in 1,331 individuals with esophageal squamous-cell carcinoma (ESCC), with associations validated in 2 independent sets including 1,962 individuals with this cancer. We identified rs1050631 in SLC39A6 as associated with the survival times of affected individuals, with the hazard ratio for death from ESCC in the combined sample being 1.30 (95% confidence interval (CI) = 1.19-1.43; P = 3.77 × 10(-8)). rs7242481, located in the 5' UTR of SLC39A6, disturbs a transcriptional repressor binding site and results in upregulation of SLC39A6 expression. Immunohistochemical staining of ESCC tissues showed that higher expression of SLC39A6 protein was correlated with shorter length of survival in individuals with advanced ESCC (P = 0.013). Knockdown of SLC39A6 expression suppressed proliferation and invasion in ESCC cells. These results suggest that SLC39A6 has an important role in the prognosis of ESCC and may be a potential therapeutic target.
    Nature Genetics 05/2013; · 35.21 Impact Factor